Drugs Susceptibility Testing in Leprosy Patients from Côte d’Ivoire Reveals Multidrugs Resistance Combination Cases to Dapsone, Rifampicin and Ofloxacin

Coulibaly N’Golo David^1, , Dehe Bahou Roger^{1, 2}, Kakou-N’Gazoa Solange¹, Kouakou henry³, Amon Aby Christiane^{1, 2}, Sylla Aboubacar¹, Bidie Alain Dit Philippe², Bamba Vagamon³ and Dosso Mireille¹

¹Molecular Biology Platform, Pasteur Institute of Côte d'Ivoire, Route de dabou Km17, 01 BP 490 Abidjan, Côte d’Ivoire

²UFR Biosciences, Laboratory of Pharmacodynamics Biochemistry, Felix Houphouet-Boigny University, Abidjan, Côte d’Ivoire

³Follereau Raoul Institute, Adzopé, Côte d’Ivoire

Cite this paper:
Coulibaly N’Golo David, Dehe Bahou Roger, Kakou-N’Gazoa Solange, Kouakou henry, Amon Aby Christiane, Sylla Aboubacar, Bidie Alain Dit Philippe, Bamba Vagamon and Dosso Mireille. Drugs Susceptibility Testing in Leprosy Patients from Côte d’Ivoire Reveals Multidrugs Resistance Combination Cases to Dapsone, Rifampicin and Ofloxacin. American Journal of Microbiological Research. 2020; 8(4):160-163. doi: 10.12691/ajmr-8-4-6

Abstract

Leprosy is a chronic tropical infectious skin disease caused by an obligate intracellular pathogen called Mycobacterium leprae. Until now no vaccine was available so early diagnosis and treatment were the basic strategy for leprosy control. The treatment is based on combined drug therapy including Dapsone, Rifampicin, and Ofloxacin according protocols recommended by the WHO. However, anti-leprosy drugs resistance has been reported in several leprosy endemic region. The drug susceptibility testing was done by detecting mutation after sequencing of the drug resistance determining region. Côte d'Ivoire like many African countries has reaching the threshold of elimination of the disease and the PCT is available nationwide. On the basis of recurrences of therapeutic failures that could be due to misobservance of patients drug therapy or eventually due to circulating resistant strains, we evaluated the drug susceptibility in 155 patients from a leprosy care center in Côte d’Ivoire. Patients were previously diagnosed by clinicians and confirmed by PCR then the genetic drug susceptibility was done by PCR-direct sequencing of the drug resistance determining region of rifampicin, dapsone and ofloxacin used in the treatment. Our results showed multiple cases of multiresistance to anti-leprosy drugs in Côte d’Ivoire. This should be an alert for antibiotic resistance observatories, and policies so that more active surveillance was carried out for the control and surveillance of M. leprae resistance to drugs.

Keywords:
leprosy M. leprae multidrug resistance Côte d’Ivoire

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	World Health Organisation study group. Chemotherapy of leprosy for control program. WHO technical report series Geneva. 1982; 675: 1-36.
[2]	World Health Organization. (‎1998)‎. Global leprosy distribution in 1998. Weekly Epidemiological Record, 73 (‎25)‎, 188-190.
[3]	Kai M, Nguyen Phuc NH, Nguyen HA, Pham TH, Nguyen KH, Miyamoto Y, Maeda Y, Fukutomi Y, Nakata N, Matsuoka M, Makino M, Nguyen TT. Analysis of drug-resistant strains of Mycobacterium leprae in an endemic area of Vietnam. Clin Infect Dis. 2011 Mar 1; 52(5): e127-32.
[4]	WHO/ Department of Control of Neglected Tropical Diseases (2009). Global leprosy situation, 2009 Weekly epidemiological record, 33(84), 333-340.
[5]	Levy L, Ji B. The mouse foot-pad technique for cultivation of Mycobacterium leprae. Lepr Rev. 2006 Mar; 77(1): 5-24. Erratum in: Lepr Rev. 2006 Jun; 77(2): 170. PMID: 16715686.
[6]	World Health Organisation: A guide for antimicrobial resistance in leprosy update 2017.
[7]	Avanzi C, Busso P, Benjak A, Loiseau C, Fomba A, Doumbia G, Camara I, Lamou A, Sock G, Drame T, Kodio M, Sakho F, Sow S O, Cole S T, Johnson R C, Transmission of Drug-Resistant Leprosy in Guinea-Conakry Detected Using Molecular Epidemiological Approaches, Clinical Infectious Diseases, Volume 63, Issue 11, 1 December 2016, Pages 1482-1484.
[8]	Chomczynski P and Sacchi N. (1987). Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction. Analytical Biochemistry. (162) 156-159.
[9]	Woods SA, Cole ST. A family of dispersed repeats in Mycobacterium leprae. Mol Microbiol. 1990 Oct; 4(10): 1745-51.
[10]	Maeda S, Matsuoka M, Nakata N, Kai M, Maeda Y, Hashimoto K, Kimura H, Kobayashi K, Kashiwabara Y. Multidrug resistant Mycobacterium leprae from patients with leprosy. Antimicrob Agents Chemother. 2001 Dec; 45(12): 3635-9.
[11]	Kumar S, Stecher G, Tamura K. MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets. MolBiolEvol. 2016 Jul; 33(7): 1870-4.
[12]	Siwakoti S, Rai K, Bhattarai NR, Agarwal S, Khanal B. Evaluation of Polymerase Chain Reaction (PCR) with Slit Skin Smear Examination (SSS) to Confirm Clinical Diagnosis of Leprosy in Eastern Nepal. PLoSNegl Trop Dis. 2016 Dec 27; 10(12): e0005220.
[13]	Izzaty Dalawi, Min Moon Tang, Amrish Shah Osman, Muhamad Ismail, Rehan Shuhada Abu Bakar, Jiloris F. Dony, Johari Zainol, AsmahJohar; Drug resistance pattern of Mycobacterium leprae from mouse footpad cultivation between 1997 to 2013 in Malaysia; Leprosy Review; 2017; 88; 4; 463-477.
[14]	Jamil S, Keer JT, Lucas SB, Deckrell HM, Chiang TJ, Hussain R, Stoker NG 1993. Use of the polymerase chain reaction to access efficacy of leprosy chemotherapy. Lancet 342: 264-267.
[15]	Sekar B, Arunagiri K, Kumar BN, Narayanan S, Menaka K, Oommen PK. Detection of mutations in folp1, rpoB and gyrA genes of M. leprae by PCR- direct sequencing--a rapid tool for screening drug resistance in leprosy. Lepr Rev. 2011 Mar;82(1): 36-45. PMID: 21644470.
[16]	Li W, Sakamuri RM, Lyons DE, Orcullo FM, Shinde V, Dela Pena EL, Maghanoy AA, Mallari IB, Tan EV, Nath I, Brennan PJ, Balagon M, Vissa V. Transmission of dapsone-resistant leprosy detected by molecular epidemiological approaches. Antimicrob Agents Chemother. 2011 Nov; 55(11): 5384-7.
[17]	Williams DL, Gillis TP. Molecular detection of drug resistance in Mycobacterium leprae. Lepr Rev. 2004 Jun; 75(2): 118-30. PMID: 15282962.
[18]	Matsuoka M. Drug resistance in leprosy. Jpn J Infect Dis. 2010 Jan; 63(1): 1-7. PMID: 20093754.
[19]	Singh P, Cole ST. Mycobacterium leprae: genes, pseudogenes and genetic diversity. Future Microbiol. 2011 Jan; 6(1): 57-71.
[20]	Sekar B, Arunagiri K, Kumar BN, Narayanan S, Menaka K, Oommen PK. Detection of mutations in folp1, rpoB and gyrA genes of M. leprae by PCR- direct sequencing--a rapid tool for screening drug resistance in leprosy. Lepr Rev. 2011 Mar; 82(1): 36-45. PMID: 21644470.
[21]	Beltrán-Alzate, Camilo, Fernando López Díaz, M. Romero-Montoya, R. Sakamuri, Wei Li, M. Kimura, P. Brennan and N. Cardona-Castro. Leprosy Drug Resistance Surveillance in Colombia: The Experience of a Sentinel Country. PLoS Neglected Tropical Diseases 10 (2016): n. pag.
[22]	Dehe BR, Coulibaly ND, Amon AC, Sylla A, Kouakou H, Kakou-Ngazoa SE, Bidie Alain DP and Bamba V. Molecular detection of mutations in rpoB gene involved in rifampicin resistance in leprosy patients in Côte d'Ivoire. World Journal of Biology Pharmacy and Health Sciences, 2(1), 01-08.
[23]	Moraes MO. Editorial Commentary: Drug-Resistance in Leprosy: Moving Toward Understanding the Scope of the Problem and How to Tackle It. Clin Infect Dis. 2016 Dec 1; 63(11): 1485-1486.